Departments of Pathology, Turku University Hospital, Turku, Finland.
Anticancer Res. 2012 Aug;32(8):3485-93.
The features of Libyan patients with breast cancer have not been fully investigated. The aim of this study was to evaluate the expression patterns of estrogen (ER) and progesterone receptor (PR), as well as nuclear morphometric features, in patients with breast cancer, and to correlate them with clinicopathological features and prognosis.
Data for a total of 62 female Libyan patients with breast cancer, diagnosed between 2000 and 2006, were retrospectively studied. Their clinical and pathological data were collected and analysed. Immunohistochemical evaluation of ER and PR expression was also performed. Further more nuclear morphometry was carried out.
Of the 62 patients, disease in 10 was of the lobular type, 43 had invasive ductal and 9 had other carcinoma types; 47 out of 62 had lymph node involvement. Positive hormonal receptor expression was more common among those with lymph node-negative than lymph node-positive tumours. ER- and PR-positive patients appeared to have a better survival than ER- and PR-negative patients. The most significant difference, with respect to survival, was found between those bearing tumors with completely negative hormonal staining (J score 0) and those with positive staining (J score 1, 2 and 3). Larger nuclear size was associated with lymph node involvement and high-grade tumours (p<0.01 and p<0.0001, respectively), with shorter survival, larger tumour size and higher stage.
The cut-off points for defining the groups with good or worse prognosis might be set, between score 0 and 1 (corresponding to 1% or fewer positive cells). Patients with ER- and PR-positive cancer had better overall survival than patients with hormonal receptor-negative cancer. In our hospital setting, ER and PR expressions and mean nuclear area (MNA) in breast carcinoma may be prognostically useful markers in guiding future treatment in prospective studies.
利比亚乳腺癌患者的特征尚未得到充分研究。本研究旨在评估乳腺癌患者中雌激素（ER）和孕激素受体（PR）的表达模式，以及核形态计量学特征，并将其与临床病理特征和预后相关联。
回顾性研究了 2000 年至 2006 年间诊断的 62 例利比亚女性乳腺癌患者的临床和病理资料。进行了 ER 和 PR 表达的免疫组织化学评估。此外，还进行了核形态计量学检查。
62 例患者中，10 例为小叶癌，43 例为浸润性导管癌，9 例为其他癌型；62 例中有 47 例淋巴结受累。无淋巴结转移的肿瘤中，激素受体阳性表达更为常见。ER 和 PR 阳性患者的生存情况好于 ER 和 PR 阴性患者。在生存方面，J 评分 0 的肿瘤与 J 评分 1、2 和 3 的肿瘤之间存在最显著差异。较大的核大小与淋巴结受累和高级别肿瘤相关（p<0.01 和 p<0.0001），与较短的生存时间、较大的肿瘤大小和较高的分期相关。
可以设定分界点，将具有良好或较差预后的组定义为 J 评分 0 与 1 之间（对应于 1%或更少的阳性细胞）。ER 和 PR 阳性癌症患者的总生存情况好于激素受体阴性癌症患者。在我们的医院环境中，ER 和 PR 表达以及平均核面积（MNA）在乳腺癌中可能是有预后意义的标志物，可在未来的前瞻性研究中指导治疗。
